Drug Profile
PF 6671008
Alternative Names: PF-06671008; PF-6671008Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer Pfizer
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cadherin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (Parenteral)
- 29 Jul 2019 PF 6671008 is still in phase I development in Solid tumours
- 13 May 2019 Pfizer terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (parenteral) (NCT02659631)